Ruxolitinib Cream Hit 79% Response Rate in HS Phase 2 Trial
A phase 2 trial found ruxolitinib 1.5% cream (Opzelura) produced a 79% response rate in mild to moderate hidradenitis suppurativa. Phase 3 trials are now underway.
Section
Treatments & Spa
Menopause Consultations Jump Among Facial Plastic Surgery Patients
GLP-1 Weight Loss Is Reshaping Breast Surgery Demand
AlloClae, the Cadaver-Fat Body Injectable, Is Up 1,300% in Searches
Dermatologist Breaks Down Seven Facts About Sculptra Before You Book
Thread Lifts Split the Experts: Barbed vs. Smooth vs. Twisted
Wait Six to Eight Hours Before Working Out After Botox, Experts Say
